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Background: Monosodium glutamate (MSG) is often thought to be associated with headache and craniofacial pains
like temporomandibular disorders. This randomized, double-blinded, placebo-controlled study was performed to
investigate how ingestion of MSG affects muscle pain sensitivity before and after experimentally induced muscle pain.
Methods: Sixteen healthy adult subjects participated in 2 sessions with at least 1-week interval between sessions.
In each session, two injections of glutamate (Glu, 0.5 M, 0.2 ml) and two injections of saline (0.9 %, 0.2 ml) into the
masseter and temporalis muscles, respectively, were undertaken, with a 15 min interval between each injection.
Injections of saline were made contralateral to Glu injections and done in a randomized order. Participants drank
400 mL of soda mixed with either MSG (150 mg/kg) or NaCl (24 mg/kg, placebo) 30 min before the intramuscular
injections. Pressure pain thresholds (PPT), autonomic parameters and pain intensity were assessed prior to (baseline)
and 30 min after ingestion of soda, as well as 5 min and 10 min after the intramuscular injections and at the end of the
session. Whole saliva samples were collected prior to and 30, 45, 60, and 75 min after the ingestion of soda.
Results: MSG administration resulted in a significantly higher Glu level in saliva than administration of NaCl and was
associated with a significant increase in systolic blood pressure. Injections of Glu were significantly more painful than
injections of NaCl. However, ingestion of MSG did not change the intensity of Glu-evoked pain. Glu injections also
significantly increased systolic and diastolic blood pressure, but without an additional effect of MSG ingestion. Glu
injections into the masseter muscle significantly reduced the PPT. However, pre-injection MSG ingestion did not
significantly alter this effect. Interestingly, PPT was significantly increased in the trapezius after MSG ingestion and
intramuscular injection of Glu in the jaw muscles.
Conclusion: The main finding in this study was that systemic intake of a substantial amount of MSG does not
influence either pain intensity or pressure pain sensitivity in the masseter and temporalis muscles into which Glu
injections were made.
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We have previously reported that injection of glutamate
(Glu) into the masseter muscle of healthy subjects causes
experimental muscle pain with features comparable to the
pain suffered in myofascial temporomandibular disorder
(TMD) [1]. Specifically, intramuscular injection of Glu
produces pain in healthy subjects that is not different in
intensity and quality from pain reported by patients with
myofascial TMD [1]. Injection of Glu into the masseter
muscle also produces punctate mechanical sensitization
which is similar, though of a lesser magnitude, to that re-
ported by myofascial TMD patients. We have suggested
that experimental designs based on glutamate injection
into masticatory muscle can provide an appropriate model
for studying myofascial TMD pain [1].
One of the reasons that intramuscular Glu injections
may replicate symptoms of myofascial TMD pain in
healthy subjects is that interstitial Glu concentrations have
been shown to be elevated in patients with myofascial
TMD [2]. One way that Glu concentrations can be ele-
vated is by consumption of excessive amounts of monoso-
dium glutamate (MSG) containing foods. In healthy
subjects, a single oral ingestion of 150 mg/kg of MSG re-
sulted in subjective reports of peri-cranial muscle tender-
ness and increased headache [3]. Oral administration of
150 mg/kg of MSG increases interstitial Glu concentration
in the masseter muscle by up to 750 % over baseline con-
centrations for a period of about 90 min [4]. Recent workFig. 1 The experimental design of this study is shown. At baseline (BL), 15 m
and after again 90 min after systemic administration of monosodium glutama
reported by each participant. The participants were asked to draw painful are
measured in the left and right Masseter (MAL, MAR), left and right Temporalis
diastolic blood pressure (sBP, dBP) and heart rate (HR). The participants were a
Saliva samples were collected at baseline, just before each injection was applindicates that repeated daily administration of MSG orally
to healthy individuals leads to more frequent reports of
adverse effect, such as headache and nausea and results in
a transient but significant lowering of pressure pain
threshold and tolerance in the masseter muscle [5].
The aim of this randomized, double-blinded, placebo-
controlled, cross-over study was to investigate whether
prior oral ingestion of MSG could alter pain and mech-
anical sensitivity induced by intramuscular injection of
Glu into the masseter muscle. We hypothesized that in-
creased interstitial Glu concentration in the masseter
muscle after oral ingestion of MSG would increase Glu-




Sixteen healthy adult (>18 years old) participants (8 women
and 8 men, mean age ± SD: 24.9 ± 4.7 years old, mean
bodyweight ± SD: 62.1 ± 13.7 kg) participated in this study.
They were recruited by an advertisement posted at Aarhus
University and through a webpage (www.forsoegsperson.
dk). Exclusion criteria were: orofacial pain, any chronic
illness, e.g. uncontrolled hypertension, allergy to MSG,
asthma, diabetes mellitus, body mass index > 25. Informed
consent was obtained from all participants. The study
protocol was approved by the local ethics committee (ap-
proval No. 20060040 – amendment No. 2 of March 2010)in after the systemic administration, 5 and 10 min after each injection,
te (MSG) or NaCl, numeric rating scale (NRS) of pain intensity was
a at the same time points as NRS. Pressure pain threshold (PPT) was also
, the right Trapezius (TRP), the left Thenar (TH), together with systolic and
sked to report adverse effects 15 min after the systemic intervention.
ied, and 90 min post oral ingestion of MSG or NaCl
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The study was conducted in accordance with the Declar-
ation of Helsinki.Study design
This study was performed as a randomized, double-
blinded, cross-over trial. Randomization was performed
by a research assistant. The examiner was blinded until
data collection on all participants was completed.
Figure 1 shows the experimental protocol of this study.
Each participant participated in 2 sessions with at least 1-
week interval between sessions. The participants were
asked to fast at least 2 h before the experiment [4]. Sessions
began with the participants sitting comfortably on a dental
chair in supine position. The participants first drank
400 mL sugar-free lemon soda (Spirit light®, Coop,
Denmark) mixed with either MSG (150 mg per kg
bodyweight) or sodium chloride (NaCl; 24 mg per kg body-
weight; placebo), in a randomized order [3, 4]. Experimen-
tal muscle pain in both the masseter and temporalis
muscles was produced by injection of a sterile solution of
glutamate (Glu: 0.5 M, 0.2 mL) 30 min after the systemic
administration of MSG or placebo. On the contralateral
side of the injected side in both the masseter and tempor-
alis muscles, isotonic saline (IS: 0.9 %, 0.2 mL) was admin-
istered as a control. Four injections in total were given with
15 min interval (Fig. 1). The injections were performed
manually over a 10-s period with a 27-gauge hypodermic
needle and a disposable syringe [6]. Both the examiner and
participants were blinded to the order and type of the injec-
tions that were given. Injection of Glu or IS were random-
ized for each subject. A research assistant prepared both
the injections and the drink in a separate room.Saliva samples
To analyze the Glu concentration in whole saliva, saliva
samples were collected 30, 45, 60, and 75 min after the
oral administration of MSG as well as baseline and post-
session. The saliva samples were collected by a commer-
cially available collection kit, Salivette™ (Sarstedt AG &
Co, Nümbrecht, Germany) [7, 8]. A kit of Salivette™ con-
sists of a plastic tube that has a partition dividing upper
and lower part, a cotton roll sheathed in the upper part
of the tube, and a lid. The participants were asked to
chew the cotton roll for 1 min and put it back into the
tube. There was a small hole in the partition of the tube
so that saliva absorbed into the cotton roll was stored in
the bottom part of the tube after the tube was
centrifuged at 1000 g for 2 min. The sample was stored
at −80 °C. The concentration of glutamate in saliva
samples was analyzed according to the previously pub-
lished work [4].Pressure pain thresholds (PPT) and autonomic parameters
PPTs on the masseter (right and left), the temporalis (right
and left), trapezius (right), and thenar (left) muscles were
measured with an electronic pressure algometer (Somedic,
Sweden) at baseline, 15 min after oral administration of
MSG, 5 and 10 min after each injection, and at the end of
the session (90 min post oral ingestion of MSG). Sites
assessed for PPT on each muscle were as follows: mas-
seter muscle; the most prominent point during contrac-
tion, approximately 2 cm superior of the mandibular
border, temporalis muscle; the most prominent point dur-
ing contraction in the anterior area of the muscle, trapez-
ius muscle; the point halfway between C7 and acromion,
thenar muscle; the middle of thenar eminence. The diam-
eter of the algometer was 1 cm and rate of increase pres-
sure was 30 kPa/s [9, 10]. The PPT was measured in
triplicates at each time point. At the same time point as
the PPT measurements, heart rate (HR) as well as systolic
and diastolic blood pressure (sBP, dBP) were measured
with a digital blood pressure monitor (UA-767 puls; A&D
Medical, Abington, UK) [3, 4].
Pain characteristics and adverse effects
All participants were instructed to rate any pain on a 0–10
numeric rating scale (NRS) at several time points: 15 min
after the oral MSG administration, 5 and 10 min after the
local Glu injection as well as at baseline and at the end of
each session (Fig. 1). On the NRS scale, 0 indicated “not
painful at all” and 10 indicated “the most pain imaginable”.
The participants were asked to draw their maximum
distribution of perceived pain on lateral views (from the
right and left side) of the face [11]. The pain area was
digitized and expressed as arbitrary units (Sigma scan
Pro 4.01.003) [1, 12].
Statistical analysis
A paired t-test was performed to test a significant difference
in the mean NRS scores between the Glu and IS injections.
For analysis of Glu concentration in the saliva samples, a
two-way ANOVA was used with session (two levels: MSG
and placebo) and time (six levels: Baseline, 30, 45, 60,
75 min after the systemic intervention, and the Post) as
main factors. A three-way analysis of variance (ANOVA)
model for repeated measures was used to analyze the PPT
values from the masseter, temporalis, trapezius and thenar
muscles as well as the autonomic parameters. The factors in
the ANOVA were session (two levels: MSG and placebo),
type of the injections (two levels: Glu and IS), time (BL,
15 min after the oral intervention, 5 min and 10 min after
the injection, and the Post). When appropriate, post hoc
tests were performed with Tukey Honestly Significant Dif-
ference (HSD) test with correction for multiple compari-
sons. The occurrence of adverse effects was compared
between sessions with Fisher’s exact test. The data are
Fig. 2 The bar graphs show the mean (±SE) pain intensity ratings 5 and 10 after injection of glutamate (Glu) or isotonic saline (IS) into the
masseter or temporalis muscles. The black bars show the result from the monosodium glutamate (MSG) session, whereas the white bars show
the results from the placebo session. *: P < 0.05. N = 16
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P < 0.05 was considered statistically significant.
Results
Experimental pain
In both the MSG and placebo sessions, the mean pain in-
tensity 5 min after Glu injection into the masseter or tem-
poralis muscles was significantly higher than the IS
injection into the same muscles (P < 0.001) (Fig. 2). TheFig. 3 The bar graphs show the mean (±SE) areas of perceived pain drawn
glutamate (MSG) session, where as white bars show that of the Placebo sepain intensity produced by Glu injections had significantly
decreased by 10 min post injection in both muscles (P <
0.001). There was no significant difference in the pain in-
tensity at any time point between the MSG and placebo
sessions (P > 0.333). Glu injection into either muscle re-
sulted in pain drawing areas that were significantly larger
than those drawn after IS injection into the same contralat-
eral muscle (P < 0.001) (Fig. 3). There was no effect of pre-
ingestion of MSG on the pain drawing area (P < 0.001).by the participants. Black bars shows the result of the monosodium
ssion. *: P < 0.05. N = 16, AU = arbitrary units
Fig. 4 The line and scatter plot illustrates the mean (± SEM) relative changes in glutamate concentration in saliva in the monosodium glutamate (MSG)
(closed circles) and placebo (open circles) sessions. P < 0.05. N = 16. * shows a significant difference compared to the baseline. $ indicates a significant
difference between sessions
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The ANOVA analysis of the Glu concentration in saliva
samples showed a significant effect of session (P = 0.013,
F = 8.656), time (P < 0.001, F = 5.406), and interaction be-
tween session and time (P = 0.004, F = 3.922). Post hoc
analysis showed that the Glu concentration increased
significantly 30 and 45 min after the systemic adminis-
tration of MSG, compared to the baseline level (30 min:
P = 0.048, 45 min: P = 0.035). Moreover, the Glu concen-
tration in the MSG session was significantly higher than
the placebo session though the entire experiment (P <
0.05) (Fig. 4).
PPT and autonomic parameters
The ANOVA analyses of the PPT values and autonomic
parameters (sBP, dBP and HR) are shown in Table 1. FiveTable 1 Results of ANOVA [P value (F value)]
Session (S) Injection (I) Time (T)
PPT
MA NS 0.021 (5.654) < 0.001 (7.364)
TA NS NS < 0.001 (7.398)
TRP 0.045 (4.114) NS < 0.001 (6.839)
TH NS NS < 0.001 (10.012)
sBP NS NS < 0.001 (16.311)
dBP NS NS < 0.001 (36.462)
HR < 0.001 (18.822) NS 0.003 (4.116)
Abbreviations





sBP: systolic blood pressure
dBP: diastolic blood pressure
HR: heart rateminutes after injection of Glu into the masseter muscle,
the PPT was significantly decreased regardless of the sys-
temic intervention (MSG: P = 0.017, Placebo: P = 0.007;
Fig. 5a). In the placebo session, the PPT value in the mas-
seter muscle 5 min after the Glu injection was significantly
lower than that after the IS injection (P = 0.004). On the
other hand, the PPT value in the trapezius increased sig-
nificantly 5 and 10 min after the Glu injection in the MSG
session (5 min: P = 0.049, 10 min: P = 0.011; Fig. 5c). Ten
minutes after the Glu injection, the PPT value of the tra-
pezius in the MSG session was significantly higher than
that in the placebo session (Fig. 5c).
The Glu injection significantly increased sBP 5 min after
the injection in both the MSG and placebo session (MSG:
P < 0.001, Placebo: P = 0.006; Fig. 6a). In the MSG session,
sBP 5 min after the Glu injection was significantly higherS x I S x T I x T S x I x T
NS NS 0.018 (3.040) NS
NS NS NS NS
NS 0.001 (4.615) NS NS
NS 0.006 (3.624) NS NS
NS NS < 0.001 (6.952) NS
NS < 0.001 (6.206) < 0.001 (11.025) NS
NS < 0.001 (5.582) NS NS
Fig. 5 The overall mean (± SEM) relative changes in pressure pain threshold (PPT) of the masseter (Ma-ipsi: a) and the temporalis muscles (Ta-ipsi: b)
on the ipsilateral side of the injection, Trapezius (c) and Thenar (d). P < 0.05. N = 16. * shows a significant difference compared to the baseline. $ shows
a significant difference between the glutamate (Glu) and isotonic saline (IS) injections in the placebo session. # shows a significant difference between
the monosodium glutamate (MSG) and the placebo sessions after the Glu injection
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was a significant increase in dBP 15 min after the systemic
MSG intervention prior to injection of Glu (P = 0.001),
which lasted until 5 min after the first Glu injection (P <
0.001; Fig. 6b). dBP was also significantly increased 5 min
after the Glu injection after the systemic placebo interven-
tion, (P < 0.001). The increase of dBP 5 min after the Glu
injection showed a significant difference, compared to that
after the IS injection in both MSG and placebo sessions
(MSG: P < 0.001, Placebo: P = 0.025; Fig. 6b). A significant
effect of the systemic MSG intervention was also observed
in HR (Fig. 6c). Even before the injections, 15 min after the
systemic intervention, HR in the MSG session was higher
than in the placebo session (P = 0.008). In the placebo ses-
sion, HR 5 min after the IS injection decreased signifi-
cantly, compared to the baseline (P = 0.038), which alsodiffered significantly from that in the MSG session (P =
0.039).
Adverse effects
The percentage of participants reporting adverse effects
15 min after systemic administration are shown in Table 2.
The frequency of participants who reported dizziness in
the MSG session was significantly higher than in the pla-
cebo session (P < 0.043).
Discussion
The present study was performed to investigate whether
MSG consumption alters muscle pain and mechanical
sensitivity produced by an experimental pain stimulus
that has some of the characteristics of muscle pain re-
ported by myofascial TMD patients. The main finding
Fig. 6 The overall mean (± SEM) relative changes in systolic blood pressure (sBP) (a), diastolic blood pressure (dBP) (b) and heart rate (HR) (c). P <
0.05. N = 16. * shows a significant difference compared to the baseline. $ shows a significant difference between the glutamate (Glu) and isotonic
saline (IS) injections within a session. § shows a significant difference between the monosodium glutamate (MSG) and the placebo sessions. #
shows a significant difference between sessions after the IS injection
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amount of MSG does not influence either pain intensity
or pressure pain sensitivity in the masseter and tempor-
alis muscles into which Glu injections were made.
Unexpectedly, the systemic intake of MSG decreased
mechanical pain sensitivity in the trapezius muscle after
Glu was injected into either the masseter or temporalis
muscles.Table 2 Occurrence of adverse effects in 16 participants (%)
Nausea Stomachache Dizziness Chest pressure H
MSG 43.8 31.3 31.3 25.0 1
Placebo 12.5 6.3 0.0 0.0 0
NS NS P < 0.043 NS NMethodological considerations
In a previous study, healthy subjects who ingested
150 mg/kg of MSG had significantly elevated interstitial
concentrations of Glu in their masseter muscles be-
tween 40 and 80 min after ingestion [4]. The average
peak masseter muscle interstitial concentrations of Glu
after a single ingestion of MSG was ~ 75 μM, and the
Glu concentration remained above 50 μM for at leasteadache Burning sensation Soreness in jaw muscles Fatigue
2.5 12.5 6.3 6.3
.0 0.0 0.0 0.0
S NS NS NS
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four intramuscular injections were applied while inter-
stitial Glu concentrations in the masseter would be sig-
nificantly higher than baseline. Although there was no
correlation between peak levels of Glu in dialysate sam-
ples and saliva samples, Glu concentrations in saliva
and muscle both increased after oral administration of
MSG in the previous study [4]. Therefore, the salivary
Glu levels measured in this study could differentiate the
MSG and placebo sessions, and indicate that subjects
would have had substantially increased muscle interstitial
concentrations of Glu after ingestion of MSG. Thus, the
lack of difference in pain intensity and mechanical
sensitization when the two sessions were compared is un-
likely to be a result of failure of the subjects to be exposed
to increased systemic levels of Glu. Further, it has been
shown in rats that when the concentration of interstitial
Glu in the masseter muscle was increased to ~75 μM,
mechanical sensitization of the muscle nociceptors was
maintained until the concentration dropped below 30 μM
[13]. However, in previous studies in healthy subjects, a
single oral dose of MSG (150 mg/kg) did not result in a
significant lowering of the PPT in the masseter or tempor-
alis muscle, but subjects did report subjective pericranial
muscle tenderness [3, 5]. It is possible that in healthy hu-
man subjects, glutamate concentrations in the masseter
muscle would need to be greater than those produced by
ingestion of a single dose of 150 mg/kg MSG to produce
measurable changes in PPT. This may have contributed to
the lack of difference in PPTs in the masseter and tempor-
alis muscles when oral consumption of MSG and placebo
were compared.
It is possible that injection of a different noxious sub-
stance, rather than Glu, into the masseter or temporalis
muscle might have resulted in a different outcome. For ex-
ample, the pain intensity and area of pain drawings were
both significantly greater when capsaicin was injected into
the masseter muscle 25 min after injection of Glu (1 M),
when compared with injection of isotonic saline [14].
However, no difference in mechanical sensitization was
seen when capsaicin injections preceded Glu injections.
There is also the potential for prolonged maintenance of
elevated Glu concentrations in skeletal muscles to cause
desensitization of Glu receptors after ingestion of MSG
[14, 15], which might explain why we failed to see an ef-
fect of MSG on Glu evoked masseter and temporalis
muscle pain. In anesthetized rats, repeated injection of
Glu into the same temporomandibular joint at intervals of
less than 30 min resulted in substantially decreased reflex
jaw muscle responses, which suggests that clearance of
Glu out of the muscle may be required to restore full noci-
ceptive responses [16].
It needs to also be considered that only healthy subjects
participated in this study. As already discussed, it ispossible that glutamate concentrations in the muscles of
healthy individuals were not elevated sufficiently to pro-
duce measurable mechanical sensitization after a single in-
gestion of MSG. Nociceptors in the masticatory muscles
of TMD patients with chronic muscle pain might be far
more sensitive to changes in interstitial glutamate concen-
trations than those in healthy subjects.
Effect of systemic glutamate administration on perceived
pain intensity and PPT
Among various risk factors for TMD, we hypothesized
that daily food consumption, especially excessive MSG
intake, might change muscle sensitivity to experimental
pain. A significantly higher interstitial concentration of
Glu [2] could trigger severe muscle pain more often in
TMD patients than the healthy individuals. However, the
systemic administration of MSG in this study did not re-
sult in higher glutamate-evoked pain intensity, compared
to placebo. Also, consistent with past studies, a lower
value of the PPT in the masseter was observed in this
study, but this occurred regardless of the session [17, 18].
Thus, in this model of TMD-like myofascial pain, we
found no evidence that MSG alters pain sensitivity.
The trapezius muscle is one of the most reported re-
ferred pain areas in patients with TMD [19]. Glu injection
into the craniofacial region caused decreased sensitivity to
pressure stimuli in the trapezius muscle after ingestion of
MSG. Hypoalgesia in a heterotopic site of painful muscles
has been previously observed [20, 21]. Glu evoked pain
may have recruited diffuse noxious inhibitory control mech-
anisms (DNIC), which could have decreased the excitability
of spinal dorsal horn neurons that receive sensory input
from the trapezius muscle [22]. This mechanism could ex-
plain the increase in the PPT in the trapezius muscle, even
though it is located outside the painful area in the tempor-
alis or masseter muscle. However, it is also possible that this
finding of hyposensitivity in the trapezius muscle could be
biased by a type II error and the multiple comparisons of
PPT data.
Effect of MSG administration on autonomic parameters
In previous studies, it has been found that oral ingestion
of 150 mg/kg MSG increases sBP by 5-10 % for 30–60
min, with a more variable effect on dBP and heart rate, al-
though heart rate usually declines [3, 5]. In the present
study, it was found that sBP and dBP were significantly in-
creased by intramuscular injection of Glu into the mas-
seter or temporalis muscle. It is possible that the increase
observed in both systolic and diastolic blood pressure
5 min after Glu injections was due to the muscle pain pro-
duced by the injections. In rats, injection of NMDA, a se-
lective Glu receptor subtype agonist, into the temporalis
muscle was shown to significantly increase mean blood
pressure [23]. This effect is likely due to a combination of
Shimada et al. The Journal of Headache and Pain  (2015) 16:68 Page 9 of 9the nociceptive input from the injection of NMDA into
the muscle, coupled with a positive inotropic effect of
NMDA on the heart after it is cleared from the muscle
into the systemic circulation. It is uncertain whether the
increased blood pressure observed in the present study
after intramuscular Glu injection in healthy subjects is a
result of pain alone, or is also reflects a positive inotropic
effect of the injected Glu on the heart.Conclusion
The present study suggests that acute experimental intake
of excessive MSG does not greatly affect muscle pain sen-
sitivity in healthy subjects. Similar to results in previous
studies, the most significant effect of systemic MSG ad-
ministration was to increase blood pressure. As Glu injec-
tion into the masseter muscle can replicate some of the
symptoms reported by patients with myofascial TMD, this
study suggests that elevated dietary intake of MSG would
likely not affect pain sensitivity in TMD patients. Future
research on the relationship between MSG consumption
and pain in TMD is required to confirm this assumption.Competing interest
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